PD-1 Antikörper (PerCP-Cy5.5)
Kurzübersicht für PD-1 Antikörper (PerCP-Cy5.5) (ABIN7674317)
Target
Alle PD-1 (PDCD1) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Verwendungszweck
- PerCP-Cy5.5 Anti-Mouse CD279/PD-1 Antibody
-
Aufreinigung
- 0
-
Reinheit
- 0
-
Isotyp
- IgG2a, kappa
-
-
-
-
Applikationshinweise
- Volume per test: 5μL. Each lot of this antibody is quality control tested by flow cytometric analysis. The amount of the reagent is suggested to be used 5 μL of antibody per test (million cells in 100 μL staining volume or per 100 μL of whole blood). Please check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0. 1 % sodium azide, 1 % BSA, pH 7.3,
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freeze / thaw cycles.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- 2-8°C for 12 months (Avoid repeated freeze / thaw cycles.)
-
Haltbarkeit
- 12 months
-
-
- PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))
-
Andere Bezeichnung
- CD279
-
Hintergrund
-
Synonyms: Programmed Death-1|PD-1
Background: CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.
-
Molekulargewicht
- 0
-
Gen-ID
- 18566
-
UniProt
- Q02242
-
Pathways
- Cancer Immune Checkpoints
Target
-